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Abstract. Cerebral small vessel disease (SVD) comprises all the patho-
logical processes affecting small brain vessels and, consequently, dam-
aging white and grey matter. Although the cause of SVD is unknown,
there seems to be a dysfunction of the small vessels. In this paper, we
propose a framework comprising tissue segmentation, spatial spectral
feature extraction, and statistical analysis to study intravenous contrast
agent distribution over time in cerebrospinal fluid, normal-appearing and
abnormal brain regions in patients with recent mild stroke and SVD fea-
tures. Our results show the potential of the power spectrum for the anal-
ysis of dynamic contrast-enhanced brain MRI acquisitions in SVD since
significant variation in the data was related to vascular risk factors and
visual clinical variables that characterise the burden of SVD features.
Thus, our proposal may increase sensitivity to detect subtle features of
small vessel dysfunction. A public version of our framework can be found
at https://github.com/joseabernal/DynamicBrainMRIAnalysis.git.
Keywords: Spatial spectral analysis · Functional principal component
analysis · Dynamic brain magnetic resonance image · Cerebral small
vessel disease
1 Introduction
Small vessel disease of the brain (SVD) comprises multiple pathological processes
affecting small cerebral arteries leading to damage of white and grey matter (WM
and GM, respectively) [17]. SVD is a serious problem that has been associated
with cognitive decline, physical fragility, depression, dementia, and stroke [17].
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Although the cause(s) of SVD remain unclear, there seems to be dysfunction of
the small vessels. This issue may be studied using dynamic contrast-enhanced
MRI (DCE-MRI). However, factors such as scanner signal drift, tissue variations,
and imaging artefacts introduce systematic errors hampering assessing small
vessel dysfunction accurately.
Dynamic brain MRI acquisitions are commonly temporally sparse and spa-
tially dense. Thus, proposals usually find alternative data representations to
reduce the dimensionality of the data while retaining critical information [7, 8].
The power spectrum [1] is a common approach in digital signal processing to de-
scribe the strength of frequency components into the overall signal. It has been
successfully applied in dynamic susceptibility contrast brain MRI to characterise
neurophysiological and hemodynamic patterns of Alzheimer’s disease [8]. We hy-
pothesise that spatial spectral feature analysis of dynamic post-contrast signal
changes can identify tissue differences in tissues that relate to the burden of SVD
features and clinical factors.
In this paper, we propose a framework to study contrast signal-time tra-
jectory in healthy and pathological brain regions in dynamic contrast-enhanced
(DCE) brain MRI acquisitions. The framework comprises segmentation, spatial
spectral and functional data analyses, and statistical group comparison. The
contributions of this work are: (i) we showcase a fully functional framework to
analyse DCE-MRI acquisitions using spatial spectral and functional data anal-
yses jointly, and (ii) we describe an application of our framework to the study
of DCE-MRI signals of a relatively large cohort (n = 201) with various extents
of SVD features.
2 Methods
2.1 Analysis framework
The processing pipeline consists of three steps. First, all regions of interest are
segmented for each patient in the cohort. Second, signals measured in each brain
region are described using the power spectrum. Third, spectral features are ex-
amined using statistical tests to establish whether they vary with any of the
clinical variables. A scheme of the pipeline applied per patient is displayed in
Fig. 1. Further details of each step are provided in the following sections.
2.2 Subjects and clinical scores
We used data from a prospective study of patients with recent mild stroke and
SVD features (n = 201 subjects, 79 women). The sample clinical characteristics
have been published previously [13, 15]; those relevant to this study are sum-
marised in Table 1. The DCE-MRI acquisition parameters have been detailed
in [6]. Patients were scanned at approximately one month after the first stroke
presentation. Following a pre-contrast acquisition, an intravenous bolus injec-
tion of gadolinium was administered with the start of 20 further acquisitions
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Fig. 1: High level schematic of our processing pipeline per patient. RPS refers to
the radial power spectrum. On the left, T1, T2, ..., TTP refer to each one of the
time points. The inputs are the post intravenous gadolinium contrast brain MRI
sequences, T1-w, T2-w, FLAIR and the susceptibility-weighted images. Initially,
we segment the regions of interest using the different imaging sequences. Then,
we study the dynamic signals per region of interest using the obtained segmen-
tation masks. Next, we convert the signals to the spatial frequency domain using
the Fourier transform. Finally, we average power values over all frequencies in
concentric rings of a specific width. In the RPS column, the lines represent the
RPS compute for cerebrospinal fluid (blue), deep grey matter (orange), normal-
appearing white matter (yellow), and white matter hyperintensities (purple).
with a temporal resolution of 73s, leading to a DCE-MRI duration of about 24
minutes (≈ 21 time points). We considered only those after the 4th time point
to minimise initial perfusion effects that occur before the contrast agent is well
mixed within the blood/intravascular compartment.
The following baseline clinical and demographic variables were obtained from
the study database: biological sex (m/f), smoker (y/n), diabetes (y/n), hyper-
lipidemia (y/n) defined as a previous diagnosis, or diagnoses at time of stroke
of a total cholesterol over 5mmol/L, hypertension (y/n) defined as a previous
history of hypertension, or hypertension diagnosed at presented of stroke. Addi-
tionally, we considered visual clinical ratings recorded at inclusion. In particular,
we utilised Fazekas [2], basal ganglia perivascular spaces (BGPVS) [10], and to-
tal SVD [12] scores to account for the location, presence and size of WMH, the
existence of enlarged PVS on the basal ganglia, and the burden of four MRI
features of the SVD (lacunes, microbleeds, PVS, and WMH). We summed up
periventricular and deep WM scores to obtain a total Fazekas score that ranged
from zero to six [4, 14]. A senior and experienced neuroradiologist generated all
visual scores.
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Table 1: Clinical variables from the sample relevant for this study. The first
column lists the variables of interest, the second one shows the frequency and
approximated relative frequency of that variable.
Clinical variable No. of patients (% of the total)
Hypertension 150 (74.6%)
Diabetes 25 (12.4%)
Hyperlipidemia 120 (59.7%)
Smoker 130 (64.7%)
Fazekas score
0 6 (3.0%)
1 16 (8.0%)
2 74 (36.8%)
3 23 (11.4%)
4 32 (14.9%)
5 20 (10.0%)
6 32 (15.9%)
BGPVS score
0 3 (1.5%)
1 102 (50.7%)
2 54 (26.9%)
3 26 (12.9%)
4 16 (8.0%)
Total SVD score
0 67 (33.3%)
1 48 (23.9%)
2 46 (22.9%)
3 27 (13.4%)
4 13 (6.5%)
2.3 Segmentation of regions of interest
We examined four regions of interest comprising both normal-appearing and
abnormal brain regions: cerebrospinal fluid (CSF), deep GM (DGM), normal-
appearing WM (NAWM), and WMH. Each segmentation was performed follow-
ing the protocol described in [13]. Trained analysts double-checked and manually
edited all segmentation masks under the supervision of an experienced neurora-
diologist. To avoid partial volume effects, we eroded the resulting binary masks.
The segmentation methods were evaluated previously against manually obtained
reference segmentations, in images acquired with similar scanning parameters
and on the same scanner like the ones this study uses [13]. On 150 individuals,
the mean difference for ICV segmentations was 2.7% (95% CI ±7%). On 20 indi-
viduals, the Jaccard Index was 0.98 (95% CI = ±0.03) for WM, 0.46 (95% CI =
±0.12) for CSF, and 0.61 (95% CI = ±0.37) for WMH. In a test-retest analysis
on 14 cases comprising volunteers and patients with mild non-disabling stroke,
the coefficient of variation for repeated measurements of the segmentation tech-
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nique was 0.21 [5]. Further information concerning inter-analyst agreements can
be found in [13].
2.4 Power spectral features of the regions of interest
We characterised the signals gauged within normal-appearing and abnormal
tissues in dynamic brain MRI acquisitions using the radial power spectrum
(RPS) [1]. The steps to compute it for each time point and each region of in-
terest are three-fold. First, we selected the signal in the region of interest using
the segmentation masks. Second, we used the 2D discrete Fourier transform to
obtain a representation of each axial slice forming the region of interest in the
frequency domain. Let I ∈ RN×N×K be a brain MR volume with K axial slices
and fk(x, y) be its k-th axial slice, the corresponding discrete Fourier transform
for each slice, Fk(u, v), is expressed as follows
Fk(u, v) =
N−1∑
i=0
N−1∑
j=0
fk(i, j) exp
(
−2ιpi
(
ui
N
+
vj
N
))
. (1)
Third, we computed the magnitude spectra and averaged all the frequencies over
concentric rings of width 1 using the following formula
R(s) =
1
K
K∑
k=1
1
2pi
∫ 2pi
0
|Fk(s cos(θ), s sin(θ))| dθ, (2)
where s =
√
u2 + v2 and θ = tan−1
(
v
u
)
are polar coordinates. For each time
point and each region of interest, the signal was described using 129 frequencies.
2.5 Functional data analysis
Each one of the elements of the RPS can be seen as a function in time. In such
a way, we could find the eigenvalues and eigenfunctions that better describe the
different observations. We followed the method proposed by Happ & Greven [3].
Let D = 129 be the number of elements under study at each time point, P =
201 the number of patients, and R = {R(1), ..., R(D)} the set of elements, each
of them described by the corresponding measurements, r
(j)
1 , r
(j)
2 , ..., r
(j)
P , the
overall process is four-fold. First, each variable was centred by subtracting its
mean value. Second, eigenfunctions and scores were calculated for each variable
using the functional PCA. The principal component functions were obtained
constructively by finding orthogonal functions Φ
(j)
k , k = 1, ...,M
(j), for which
principal component scores ξ
(j)
ik , i = 1, ..., P , mathematically expressed as
ξ
(j)
ik (t) =
∫
Φ
(j)
k (t) r
(j)
i (t)dt, (3)
maximised
∑
i ξ
(j)
ik
2
, subject to ||Φ(j)k ||2 = 1, were t ∈ [4, 5, 6, ..., 21] represents
each time point. We set M (j) to five as resulting eigenvectors accounting for
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the 99% of the univariate variation. Third, all of these scores ξ
(j)
ik were ar-
ranged in a matrix form, Ξ ∈ RP×
∑
M(j) , such that the ith row contained
(ξ
(1)
i1 , ..., ξ
(1)
iM(1)
, ..., ξ
(p)
i1 , ..., ξ
(p)
iM(p)
). Fourth, scores were calculated using eigenanal-
ysis on the covariance matrix of Ξ. We resorted to using the first three modes
of variation which explained around the 99% of the data variation. The output
at this stage was a score for per mode of variation for each subject.
2.6 Validation against clinical parameters
We used the Kruskal-Wallis test to determine whether the features vary with
any of the clinical parameters. We verified that the analysed variables were not
normally distributed using the Shapiro-Wilk test. The null hypothesis was that
subjects with different clinical scores exhibit similar feature values. We computed
the test in R version 3.5.1 and corrected the p-values for multiple comparisons
using the Benjamini-Hochberg false discovery rate control method.
3 Experiments and results
The application of our framework to the case study was performed as follows. We
segmented each of the 201 DCE-MRI scans, measured the signal gauged in each
region of interest using the resulting tissue masks, calculated the RPS of each
time point and each region of interest, and extracted spectral measurements.
Once we obtained the spectral features for each patient, we compared them
using statistical analysis to explore whether they vary with clinical variables.
An example of the radial power spectra calculated from signals gauged in the
WM hyperintense (WMH) regions with the lowest and highest WMH burden
is shown in Fig. 2. As it can be observed, the two groups of patients exhibit
different spectra.
We compared two functional data analysis approaches: a time-averaged and
a dynamic RPS, the latter taking signal over time into account. The corre-
sponding significance values obtained from the Kruskal-Wallis test are presented
in Table 2 and Table 3, respectively. Apart from considering the RPS of each
region of interest independently, we analysed them jointly as well. The corre-
sponding results are displayed in the column “All” of both tables. In most of
the cases, both approaches coincided. However, there were slight differences. The
spectral features computed in the CSF region varied with Fazekas scores, but
the method considering the temporal dimension exhibited stronger evidence (p-
value < 0.0001) than the time-averaged scheme (p-value < 0.001). Similarly, the
scores yielded by the dynamic RPS showed more evidence of variation with the
burden of SVD features in the DGM region (p-value < 0.05) compared to the
time-averaged RPS (p-value > 0.05). These outcomes suggest that the temporal
component is of relevance, consistent with our hypothesis [16].
The power spectrum (expressed through PC1, PC2, and PC3) varied (p-
value < 0.05) when grouped by visual clinical ratings regardless of the region
of interest, indicating that burden of SVD influenced the spectral findings. The
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Fig. 2: Radial power spectra calculated from real signals in the white matter
hyperintense regions for patients with Fazekas score 6 (red) and Fazekas score
0 and 1 (blue). Each line corresponds to the spectrum of a patient in the time
point 4. The values were normalised by the DC value for visualisation purposes.
measurements gathered from all the regions of interest varied significantly with
biological sex (p-value < 0.05), overall WMH burden (p-value < 0.001), BGPVS
scores (p-value < 0.05), and total SVD (p-value < 0.001). An example of the
distribution of principal component scores in CSF, DGM, and NAWM, according
to deep and periventricular Fazekas scores, is shown in Fig. 3. The tendency
overall was that scores decreased significantly (p-value < 0.05) with increased
WMH burden.
The power spectrum appeared to change concerning covariates such as di-
abetes, hypertension, and hyperlipidemia (p-value < 0.05), but the variations
were observed in specific regions: hypertension in NAWM, WMH and All, dia-
betes in WMH and All, and hyperlipidemia in DGM. When stratified by smoker
vs non-smoker, the signals did not differ (p-value > 0.05). In general, the power
spectrum calculated from normal-appearing and abnormal regions of interest
varied significantly mostly with clinical SVD ratings.
In terms of computational time, the manual rectification of the segmentation
boundaries consumed most of the time, being it reported to take between 20 and
60 minutes per patient for WM and WMH depending on the expertise of the
analyst. [13]. The calculation of the RPS per patient can take up to one minute,
and the computation of the PCA scores for a region of interest for all 201 patients
takes approximately two minutes on a Microsoft Windows 10 machine with 8GB
RAM (i5-4590 CPU Intel(R) processor @ 3.30 GHz).
4 Discussion
In this paper, we propose, for the first time, a framework incorporating power
spectrum analysis to study dynamic brain MRI signals of brain-related patholog-
ical processes. Our team implemented the segmentation protocols and methods,
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Table 2: Kruskal-Wallis test results obtained when comparing the functional
principal component (PC) scores extracted from the time-averaged RPS of sub-
jects grouped by clinical variables. The percentages under each one of the PC
correspond to the portion of data variability each of them describe. The column
“All” refers to the result obtained when analysing principal components of all re-
gions of interest jointly. Significant values are shown in bold. For each univariate
test, the number of samples was 201.
Clinical variable CSF DGM NAWM WMH All
PC1 PC2 PC3 PC1 PC2 PC3 PC1 PC2 PC3 PC1 PC2 PC3 PC1 PC2 PC3
98% 1% 1% 98% 1% 1% 98% 1% 1% 99% 1% 1% 84% 15% 1%
Biological sex 0.003 0.001 0.001 0.002 0.031 0.008 0.021 0.032 0.018 0.562 0.379 0.297 0.009 0.137 0.001
Smoker 0.386 0.949 0.184 0.055 0.238 0.063 0.281 0.310 0.330 0.274 0.392 0.297 0.195 0.211 0.733
Diabetes 0.060 0.697 0.042 0.825 0.874 0.892 0.281 0.168 0.287 0.032 0.392 0.596 0.259 0.938 0.004
Hyperlipidemia 0.785 0.921 0.618 0.035 0.460 0.136 0.374 0.495 0.414 0.508 0.392 0.297 0.259 0.124 0.503
Hypertension 0.060 0.380 0.047 0.471 0.874 0.752 0.021 0.012 0.022 0.021 0.379 0.297 0.019 0.938 0.091
Fazekas 0.060 0.921 0.002 0.007 0.238 0.091 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.137 0.001
BGPVS 0.060 0.697 0.002 0.106 0.419 0.313 0.021 0.012 0.034 0.001 0.013 0.001 0.006 0.162 0.001
Total SVD 0.090 0.921 0.002 0.054 0.669 0.313 0.001 0.001 0.001 0.001 0.001 0.001 0.001 0.137 0.001
the computation of the power spectrum features, and the integration of each
processing module into the proposed framework. In particular, we applied our
processing pipeline to the study of SVD tissue changes using DCE-MRI acquisi-
tions. The power spectrum gauged from normal-appearing and abnormal brain
regions of a population with features of SVD of differing extents was analysed
to explore whether patients with biological sex, hypertension and visual ratings
(namely Fazekas, BGPVS, total SVD scores) exhibited distinctive spectra. To
the best of our knowledge, this is the first time that the power spectrum has
been examined for this purpose in a relatively large cohort (n = 201) with a
wide range of SVD features. Of note, we applied our framework to the study
of DCE-MRI signals. Nonetheless, this does not prevent it from being used for
analysing other dynamic and non-dynamic brain MR acquisitions.
Due to the relative temporal sparsity and spatial density of the dynamic brain
MRI acquisitions, the number of techniques that can be used to process them
is reduced. Thus, finding adequate alternative representations is crucial. In this
paper, we explored the spectral density for studying dynamic brain MRI signals
in SVD. According to our evaluation results, we found that spectral features of
the DCE-MRI acquisitions vary significantly with biological sex, hypertension,
and clinical visual ratings (namely, Fazekas, BGPVS, and total SVD scores). This
outcome suggests that the use of the power spectrum is suitable for examining
these types of acquisitions.
We evaluated two approaches for extracting features out of the RPS. The first
one contemplated computing the mean RPS over time and studying it through
univariate functional PCA. The second one consisted of describing each element
of the dynamic RPS through multivariate functional PCA. In both cases, we
retrieved the scores resulting in the direction of the first three modes of variation.
We observed that the two approaches coincide most of the time. However, as the
former method summarises the temporal changes in the data, the latter should
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Table 3: Kruskal-Wallis test results obtained when comparing the functional
principal component (PC) scores extracted from the RPS of subjects grouped
by clinical variables. The percentages under each one of the PC correspond to
the portion of data variability each of them describe. The column “All” refers
to the result obtained when analysing principal components of all regions of
interest jointly. Significant values are shown in bold. For each univariate test,
the number of samples was 201.
Clinical variable CSF DGM NAWM WMH All
PC1 PC2 PC3 PC1 PC2 PC3 PC1 PC2 PC3 PC1 PC2 PC3 PC1 PC2 PC3
96% 3% 1% 90% 8% 2% 94% 5% 1% 93% 5% 1% 84% 15% 1%
Biological sex 0.001 0.001 0.563 0.001 0.001 0.849 0.019 0.001 0.573 0.554 0.273 0.102 0.060 0.121 0.001
Smoker 0.313 0.209 0.939 0.066 0.110 0.769 0.292 0.346 0.263 0.257 0.985 0.740 0.216 0.239 0.456
Diabetes 0.051 0.991 0.376 0.828 0.317 0.607 0.292 0.319 0.941 0.035 0.985 0.979 0.251 0.994 0.048
Hyperlipidemia 0.784 0.209 0.563 0.044 0.980 0.607 0.403 0.425 0.573 0.481 0.985 0.583 0.251 0.098 0.862
Hypertension 0.051 0.991 0.563 0.486 0.801 0.849 0.023 0.708 0.538 0.019 0.261 0.372 0.017 0.994 0.686
Fazekas 0.041 0.257 0.001 0.009 0.026 0.941 0.001 0.001 0.573 0.001 0.001 0.001 0.001 0.098 0.001
BGPVS 0.041 0.828 0.001 0.124 0.026 0.159 0.023 0.001 0.751 0.001 0.001 0.102 0.066 0.142 0.001
Total SVD 0.051 0.164 0.001 0.067 0.013 0.496 0.001 0.001 0.836 0.001 0.001 0.001 0.001 0.121 0.001
be preferred. Our experimental results support this claim and are consistent with
our hypothesis.
The spatial spectral features extracted from the signal in the NAWM re-
gion differed significantly with SVD features and their extents. This observation
agrees with previous finding in which the differentiation between “normal” and
“abnormal” tissues becomes less evident with increased age and SVD feature
severity [14]. Interestingly, a small percentage of the variations of the spectral
features in the CSF region differed significantly with SVD features and their
extents. This situation might be related to leakage of gadolinium in CSF with
increased SVD burden [14]. The Fazekas score has been found to be associ-
ated with increasing BBB leakage [9,16] and as the spectral features of patients
grouped by this visual rating were statistically different, this outcome suggests
that our framework can be used in the study of small vessel dysfunction.
Differences regarding biological sex (and presumably brain size as well) are
expected as a direct consequence of the scaling theorem of the Fourier transform
in which the size of the region of interest is linked to its Fourier representa-
tion [11]. Thus, the size of brain structures within a region of interest is expected
to be, in principle, encoded in the spectral features used. This problem may be
alleviated by processing the regions of interest in a short-time Fourier transform
or sliding-window processing fashion or by manually selecting matching and rel-
evant regions of interest with exactly the same area/volume on all scans. In the
future, we plan to explore alternatives in these regards.
In the present work, we showed that a strategy based on the study of the
power spectrum could be used to investigate dynamic post-contrast signal changes
in tissues that relate to the extents of SVD features, vascular risk factors and
clinical visual ratings. The outcomes of our experiments add confidence to previ-
ous findings in which DCE-MRI signals from patients with different age, health
status, and premorbid brain condition exhibited different tendencies [16]. For
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instance, a pre- and post-contrast texture analysis concluded that local signal
variations, measured in terms of homogeneity and contrast, differed significantly
depending on the extents of SVD features [14]. Future work should consider
understanding what physiopathological processes cause these power spectrum
variations and which aspects of the spectrum are different among patient groups.
Acknowledgements
JB holds an MRC Precision Medicine Doctoral Training Programme studentship
from the University of Edinburgh. This work was supported by the Row Fogo
Charitable Trust (MVH) grant no. BRO-D.FID3668413, Wellcome Trust (pa-
tient recruitment, scanning, primary study Ref No. WT088134/Z/09/A), Fon-
dation Leducq (Perivascular Spaces Transatlantic Network of Excellence), and
EU Horizon 2020 (SVDs@Target) and the MRC UK Dementia Research Insti-
tute (Wardlaw programme). The authors thank participants in the study, the
radiographers and staff at the Edinburgh Imaging Facilities (www.ed.ac.uk/
clinical-sciences/edinburgh-imaging/research/facilities-and-equipment/
edinburgh-imaging-facilities), the UK Dementia Research Institute at the
University of Edinburgh, and the Row Fogo Centre for Ageing and the Brain.
References
1. Chapter 3 power spectrum and its applications. In: Naidu, P.S., Mathew, M. (eds.)
Analysis of Geophysical Potential Fields, Advances in Exploration Geophysics,
vol. 5, pp. 75 – 143. Elsevier (1998)
2. Fazekas, F., Niederkorn, K., Schmidt, R., Offenbacher, H., Horner, S., Bertha, G.,
Lechner, H.: White matter signal abnormalities in normal individuals: correlation
with carotid ultrasonography, cerebral blood flow measurements, and cerebrovas-
cular risk factors. Stroke 19(10), 1285–1288 (1988)
3. Happ, C., Greven, S.: Multivariate functional principal component analysis for data
observed on different (dimensional) domains. Journal of the American Statistical
Association pp. 1–11 (2018)
4. Herna´ndez, M.D.C.V., Chappell, F.M., Maniega, S.M., Dickie, D.A., Royle, N.A.,
Morris, Z., Anblagan, D., Sakka, E., Armitage, P.A., Bastin, M.E., et al.: Metric to
quantify white matter damage on brain magnetic resonance images. Neuroradiology
59(10), 951–962 (2017)
5. Herna´ndez, M.d.C.V., Ferguson, K.J., Chappell, F.M., Wardlaw, J.M.: New multi-
spectral MRI data fusion technique for white matter lesion segmentation: method
and comparison with thresholding in FLAIR images. European radiology 20(7),
1684–1691 (2010)
6. Heye, A.K., Thrippleton, M.J., Armitage, P.A., Herna´ndez, M.d.C.V., Makin, S.D.,
Glatz, A., Sakka, E., Wardlaw, J.M.: Tracer kinetic modelling for DCE-MRI quan-
tification of subtle blood–brain barrier permeability. Neuroimage 125, 446–455
(2016)
7. Khalifa, F., Soliman, A., El-Baz, A., Abou El-Ghar, M., El-Diasty, T., Gimel’farb,
G., Ouseph, R., Dwyer, A.C.: Models and methods for analyzing DCE-MRI: A
review. Medical physics 41(12) (2014)
Analysis of spatial spectral features of DCE-MRI for studying SVD 11
8. Mattia, D., Babiloni, F., Romigi, A., Cincotti, F., Bianchi, L., Sperli, F., Placidi,
F., Bozzao, A., Giacomini, P., Floris, R., et al.: Quantitative EEG and dynamic
susceptibility contrast MRI in Alzheimer’s disease: a correlative study. Clinical
neurophysiology 114(7), 1210–1216 (2003)
9. Mun˜oz Maniega, S., Chappell, F.M., Valde´s Herna´ndez, M.C., Armitage, P.A.,
Makin, S.D., Heye, A.K., Thrippleton, M.J., Sakka, E., Shuler, K., Dennis, M.S.,
et al.: Integrity of normal-appearing white matter: influence of age, visible lesion
burden and hypertension in patients with small-vessel disease. Journal of Cerebral
Blood Flow & Metabolism 37(2), 644–656 (2017)
10. Potter, G., Doubal, F., Jackson, C., Sudlow, C., Dennis, M., Wardlaw, J.: Asso-
ciations of clinical stroke misclassification (clinical-imaging dissociation) in acute
ischemic stroke. Cerebrovascular Diseases 29(4), 395–402 (2010)
11. Smith, J.O.: Mathematics of the Discrete Fourier Transform (DFT). W3K Pub-
lishing (2007)
12. Staals, J., Makin, S.D., Doubal, F.N., Dennis, M.S., Wardlaw, J.M.: Stroke sub-
type, vascular risk factors, and total MRI brain small-vessel disease burden. Neu-
rology 83(14), 1228–1234 (2014)
13. Valde´s Herna´ndez, M.d.C., Armitage, P.A., Thrippleton, M.J., Chappell, F.,
Sandeman, E., Mun˜oz Maniega, S., Shuler, K., Wardlaw, J.M.: Rationale, design
and methodology of the image analysis protocol for studies of patients with cerebral
small vessel disease and mild stroke. Brain and behavior 5(12), e00415 (2015)
14. Valde´s Herna´ndez, M.d.C., Gonza´lez-Castro, V., Chappell, F.M., Sakka, E., Makin,
S., Armitage, P.A., Nailon, W.H., Wardlaw, J.M.: Application of texture analysis to
study small vessel disease and blood–brain barrier integrity. Frontiers in neurology
8, 327 (2017)
15. Wardlaw, J.M., Chappell, F.M., Herna´ndez, M.d.C.V., Makin, S.D., Staals, J.,
Shuler, K., Thrippleton, M.J., Armitage, P.A., Mun˜oz-Maniega, S., Heye, A.K.,
et al.: White matter hyperintensity reduction and outcomes after minor stroke.
Neurology 89(10), 1003–1010 (2017)
16. Wardlaw, J.M., Makin, S.J., Herna´ndez, M.C.V., Armitage, P.A., Heye, A.K.,
Chappell, F.M., Munoz-Maniega, S., Sakka, E., Shuler, K., Dennis, M.S., et al.:
Blood-brain barrier failure as a core mechanism in cerebral small vessel disease and
dementia: evidence from a cohort study. Alzheimer’s & Dementia 13(6), 634–643
(2017)
17. Wardlaw, J.M., Smith, C., Dichgans, M.: Mechanisms of sporadic cerebral small
vessel disease: insights from neuroimaging. The Lancet Neurology 12(5), 483–497
(2013)
12 J. Bernal et al.
ns
*
**
*
**
*
−20
0
20
40
60
0 1 2 3
Periventricular Fazekas score (0−1−2−3)
Fu
nc
tio
na
l P
C 
Sc
or
es
 −
 C
SF
(a)
ns
ns
*
*
**
*
−20
0
20
40
60
0 1 2 3
Deep white matter Fazekas score (0−1−2−3)
Fu
nc
tio
na
l P
C 
Sc
or
es
 −
 C
SF
(b)
ns
ns
**
*
**
**
0
1000
0 1 2 3
Periventricular Fazekas score (0−1−2−3)
Fu
nc
tio
na
l P
C 
Sc
or
es
 −
 D
G
M
(c)
ns
*
**
*
**
*
0
1000
0 1 2 3
Deep white matter Fazekas score (0−1−2−3)
Fu
nc
tio
na
l P
C 
Sc
or
es
 −
 D
G
M
(d)
ns
ns
**
*
**
**
0
1000
0 1 2 3
Periventricular Fazekas score (0−1−2−3)
Fu
nc
tio
na
l P
C 
Sc
or
es
 −
 N
AW
M
(e)
ns
*
**
*
**
*
0
1000
0 1 2 3
Deep white matter Fazekas score (0−1−2−3)
Fu
nc
tio
na
l P
C 
Sc
or
es
 −
 N
AW
M
(f)
Fig. 3: Distribution of PCA scores obtained for the CSF (blue), DGM (orange),
and NAWM (yellow) regions grouped by the Fazekas periventricular WM (left)
and deep WM (right) scores of the patients. The scores correspond to PC3 for
CSF, PC2 for DGM, and PC2 for NAWM. Significant differences between pairs
of groups have been highlighted with ∗p < 0.05 ∗∗p < 0.001.
